CX-546
 | |
| Clinical data | |
|---|---|
| Other names | CX-546 |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
JSmol) | |
| |
| |
  (what is this?) (verify) | |
CX-546 is an
Cortex Pharmaceuticals
.
It has been proposed as a treatment for schizophrenia.[1] CX-546 was the second drug of note to come out of the Cortex research program, after CX-516, but while it was an improvement over its predecessor in some respects, it still has problems with limited oral bioavailability.
However, CX-546 still represented a significant advance that led on to the development of newer compounds such as
barbiturates.[2]
No effective respiratory stimulants are currently marketed for this application, with CX-546 being only the third drug discovered (after
CX-1739 or CX-1763, which are likely to be more suitable for commercial development.[citation needed
]